• 3044am永利集团

      Global
      关于3044am永利集团

      致力于纳米抗体
      创新药物研发

      关于3044am永利集团
      科研论文
      截止现在，3044am永利集团生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
      2023-11-06
      TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
      发表于:J Nanobiotechnology. 2023 Nov 6;21(1):410
      查看更多内容
      2023-09-21
      Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis
      发表于:Int J Nanomedicine. 2023 Sep 21;18:5407-5422
      查看更多内容
      2022-11-19
      Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
      发表于:Respiratory Research. 2022 Nov 19;23(1):316
      查看更多内容
      2022-10-24
      Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
      发表于:Cells. 2022 Oct 24;11(21):3355
      查看更多内容
      2022-10-03
      Atomically dispersed Mn boosting photoelectrochemical SARS-CoV-2 spike protein immunosensing on carbon nitride
      发表于:Journal of Environmental Chemical Engineering. 2022 Dec;10(6):108697
      查看更多内容
      2022-07-22
      Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022
      发表于:Research (Wash D C). 2022 Jul 22;2022:9864089
      查看更多内容
      总计 24 1234